• This is the free base form of sorafenib; please see our product Sorafenib, p-Toluenesulfonate Salt, Cat. No. S-8502, for further technical information. It is the p-toluenesulfonate salt form, not the free base, that is used in the formulation of sorafenib for in vivo use.
• Sorafenib is the active ingredient in the drug sold under the trade name Nexavar®. This drug has been approved in at least one country for use in patients with advanced renal cell cancer. NOTE: The sorafenib sold by LC Laboratories is NOT Nexavar®, and is NOT for human use.
• Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.
• This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
• Not available in some countries; not available to some institutions; not available for some uses.

Related Terms:

Storage

Solubility

3 mg/mL with warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 10-50 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility.Disposal